Indeed, some SMA-MAP analytes are themselves markers or members of biological networks implicated for Amyotrophic Lateral Sclerosis (ALS), Duchene Muscular Dystrophy (DMD) or other neurodegenerative diseases: CCL2 and ENG for ALS, LUM and SPP1 for DMD, and CRP, CTSD, and IGF1 for Parkinson’s and Alzheimer’s [60], [63]–[75]. The gene discussed is SPP1; the disease is amyotrophic lateral sclerosis.